Tych.Bo

TYCH.BO maintains a strong liquidity position, with a current ratio of 12.57, indicating a significant buffer of current assets over current liabilities. The company has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure with no leverage. Free cash flow of INR 111,109,000 supports operational flexibility and potential for reinvestment or shareholder returns.

Profitability metrics show a return on equity of 9.08% and a return on assets of 8.42%, both exceeding the typical thresholds for the pharmaceutical industry, which emphasizes high returns on invested capital. Operating income of INR 93,002,000 and net income of INR 124,072,000 indicate strong earnings performance relative to revenue of INR 654,713,000.

TYCH.BO's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic diversification data available in the provided sources. This lack of segmental or geographic breakdown limits visibility into potential revenue concentration risks.

The company's growth trajectory is not explicitly outlined in the provided data, but its strong free cash flow and operating cash flow of INR 85,441,000 suggest a stable financial position that could support future expansion or R&D investment. Capital expenditures were negative at INR -7,233,000, indicating asset disposals or a reduction in capital spending.

Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure is free of dilution pressures, as shares outstanding remain unchanged between basic and diluted shares. No dilution sources were identified in the available documents.

Recent filings and transcripts do not provide specific events or strategic updates for TYCH.BO. The company's financials suggest a stable and conservative approach to capital management, with no recent material changes in its financial position.